Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -6 of 6 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 6/8/2007 First Published: 8/6/2006


1.		Phase III Randomized Study of Prophylactic Topical Sunscreen for the Prevention of Erlotinib-, Cetuximab-, or Other Epidermal Growth Factor Receptor Inhibitor-Induced Skin Rash in Patients With Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Closed				18 and over				NCI				NCCTG-N05C4 N05C4, NCCTG N05C4, NCT00362986


2.		HuMax-EGFr in Head and Neck Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				Pharmaceutical / Industry				Hx-EGFr-001 NCT00093041


3.		A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				EMD 72000-030 NCT00073541


4.		Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 to 75				Pharmaceutical / Industry				EMD 72000-031 NCT00111839


5.		MATRIX EG (Matuzumab Treatment With ECX in Esophago-Gastric Cancer)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				EMD 72000-032 NCT00215644


6.		Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				Pharmaceutical / Industry				EMD 72000 - 024 NCT00113581

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute